
|Articles|July 15, 2002
- BioPharm International-07-01-2002
- Volume 15
- Issue 7
Optimizing Recombinant Microbial Fermentation Processes: An Integrated Approach
by Karl Bayer, Monika Cserjan-Puschmann, Reingard Grabherr, Gerald Striedner, and Franz Clementschitsch, Institute of Applied Microbiology, Vienna, Austria A new strategy for controlling recombinant gene expression improves efficiency, maximizes host vector exploitation, reduces costs, improves product consistency, and accelerates product development. Continuous feeds of limited amounts of inducer proportional to biomass growth grant optimal control over the ratio between gene expression and host cell metabolism, providing stable, prolonged recombinant protein production.
Advertisement
Articles in this issue
over 24 years ago
Facilitating Client Audits: The Contract Laboratory Perspectiveover 24 years ago
Knowledge Management: The Four Pillars of Successover 24 years ago
Inside Washington: One Hundred Years of Biotech Regulationover 24 years ago
Guest Editorial: Supreme Court Rules on FestoAdvertisement
Related to this article

In the second part of a two-part interview, Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center explains how patients are monitored after a complete response to dostarlimab, what longer follow-up needs to show, and how avoiding chemoradiation and surgery changes patients' lives.

Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.

At the 2026 Jefferies Global Healthcare Conference, Leads Biolabs presented updated survival and safety data for its PD-L1/4-1BB bispecific antibody opamtistomig across seven tumor types and disclosed plans to begin antibody-drug conjugate combination programs in 2027.

Celldex's anti-KIT monoclonal antibody barzolvolimab depleted mast cells but did not meet its primary itch endpoint in a phase 2 atopic dermatitis study. The company is discontinuing development of its atopic dermatitis treatment while advancing a planned 2027 BLA in chronic spontaneous urticaria.

Innogen will receive $38 million upfront and near-term for rights to its ultra-long-acting GLP-1 efsubaglutide alfa across four emerging regions.

Sacituzumab tirumotecan is the first TROP2-directed ADC to improve overall survival in heavily pretreated gastroesophageal adenocarcinoma.

Mazen Noureddin, MD, MHSc, of Houston Methodist Hospital discusses phase 2 data for GSK's once-monthly FGF21 analog efimosfermin presented at The Liver Meeting 2026 and what the findings mean for ongoing phase 3 trials in MASH and compensated cirrhosis.

Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
Advertisement
Advertisement
Trending on BioPharm International
1
Celldex Ends Program for its Atopic Dermatitis Treatment After Phase 2 Miss Points to Limited Role for Mast Cells
2
Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer
3
AbbVie and DISCO Partner on AND-Gated Bispecifics Designed to Recognize Tumor-Selective Protein Pairs
4
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
5

